This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
End-To-End Support at Every Stage of Your Drug Development Journey
Brochures, Pharmaceutical, Device Innovations, Brand Differentiation, Product Solutions
Towards A New Standard of Care with Aptar Pharma’s Digital Health
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
Aptar Pharma discusses an antibody nasal spray for SARS-CoV-2
Publications, Pharmaceutical, Innovation & Insights, Product Solutions
Delivering On The Promises of Intranasal Vaccination
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
